Prothena Corporation PLC (PRTA) Stock Analysis
Verdict: WATCH (do not buy)
Prothena is a binary clinical-stage bet where a $307M cash runway must outlast high-burn R&D before Phase III Birtamimab data arrives.
Investment score: 48/100
Analysis as of
Is Prothena Corporation PLC stock worth reviewing? The TradeMates thesis
Prothena is the definition of a clinical binary play. With a strong cash position but deteriorating annual revenue, the model views recent insider buying as a tactical signal, yet recognizes the extreme fundamental risk inherent in its Phase III AL amyloidosis program.
7-factor investment score
- Valuation: 35/100 (weight 20%)
- Financial Health: 30/100 (weight 15%)
- Technical Momentum: 70/100 (weight 15%)
- Earnings Quality: 65/100 (weight 15%)
- Insider Sentiment: 80/100 (weight 10%)
- Analyst Consensus: 75/100 (weight 10%)
- Risk-Adjusted Return: 40/100 (weight 15%)
Prothena Corporation PLC opportunities and risks
What speaks for PRTA
- Significant Insider Commitment
What speaks against PRTA
- Severe Cash Burn Runway
Peers and competitors
- ALKS
- AMRN
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| PRTA | n/a | 9.1x | n/a | 46.8% | -260.9% | -15.5% |
| ALKS | 40.6x | 4.0x | 27.0x | 86.6% | 9.8% | 3.6% |
| AMRN | n/a | 1.4x | n/a | 52.5% | -15.6% | 8.6% |
| Peer median | 15.9x | 2.7x | n/a | 69.6% | -2.9% | 6.1% |
Frequently asked questions about Prothena Corporation PLC (PRTA)
Is PRTA stock a good investment?
The TradeMates model rates Prothena Corporation PLC as WATCH (do not buy) with an investment score of 48/100. Prothena is the definition of a clinical binary play. With a strong cash position but deteriorating annual revenue, the model views recent insider buying as a tactical signal, yet recognizes the extreme fundamental risk inherent in its Phase III AL amyloidosis program. This is algorithmic model output, not personal investment advice.
Is PRTA stock a buy?
The TradeMates model verdict for PRTA is WATCH (do not buy) with an investment score of 48/100. Treat this as a model signal to review, not a personal buy recommendation.